Epigenetic modification enhances the cytotoxicity of busulfan and4-hydroperoxycyclophosphamide in AML cells
- 1 November 2018
- journal article
- research article
- Published by Elsevier BV in Experimental Hematology
- Vol. 67, 49-59.e1
- https://doi.org/10.1016/j.exphem.2018.08.002
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81270645)
- Science and Technology Department of Jiangsu Province (BE2017655)
- Jiangsu Provincial Medical Talent (ZDRCA2016045)
- National Institutes of Health (CA016672)
This publication has 47 references indexed in Scilit:
- Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter studyJournal of Hematology & Oncology, 2013
- Mitochondria-Ros Crosstalk in the Control of Cell Death and AgingJournal of Signal Transduction, 2011
- Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AMLBlood, 2011
- The synergistic cytotoxicity of clofarabine, fludarabine and busulfan in AML cells involves ATM pathway activation and chromatin remodelingBiochemical Pharmacology, 2011
- 5-Aza-2′-deoxycytidine sensitizes busulfan-resistant myeloid leukemia cells by regulating expression of genes involved in cell cycle checkpoint and apoptosisLeukemia Research, 2010
- Altered gene expression in busulfan-resistant human myeloid leukemiaLeukemia Research, 2008
- DNA Methylation Inhibitor 5-Aza-2′-Deoxycytidine Induces Reversible Genome-Wide DNA Damage That Is Distinctly Influenced by DNA Methyltransferases 1 and 3BMolecular and Cellular Biology, 2008
- DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociationNature, 2003
- Metabolism and Pharmacokinetics of OxazaphosphorinesClinical Pharmacokinetics, 2000
- Marrow Transplantation for Acute Nonlymphocytic Leukemia after Treatment with Busulfan and CyclophosphamideNew England Journal of Medicine, 1983